Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one. 2011

Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
Department of Organic Chemistry, College of Pharmacy, Second Military Medical University, Guohe Road 325, Shanghai 200433, People's Republic of China.

Based on the structure of the active site of cytochrome P450 14α-demethylase (CYP51) and the conclusions of the structure-activity relationships of azole antifungals, a series of 1-(2-(2,4-difluoro-phenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one of fluconazole analogs was synthesized. All compounds were characterized by IR, HRMS, (1)HNMR and (13)C NMR spectroscopic analysis. Results of preliminary antifungal in vitro test using eight human pathogenic species showed that some compounds displayed comparable or even better antifungal activities than reference drug fluconazole and that compound 3i exhibited significant activity against Candida albicans being worthy of further optimization.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D005656 Fungal Proteins Proteins found in any species of fungus. Fungal Gene Products,Fungal Gene Proteins,Fungal Peptides,Gene Products, Fungal,Yeast Proteins,Gene Proteins, Fungal,Peptides, Fungal,Proteins, Fungal
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015725 Fluconazole Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. Apo-Fluconazole,Béagyne,Diflucan,Fluc Hexal,FlucoLich,Flucobeta,Fluconazol AL,Fluconazol AbZ,Fluconazol Stada,Fluconazol von ct,Fluconazol-Isis,Fluconazol-ratiopharm,Flunazul,Fungata,Lavisa,Loitin,Neofomiral,Oxifungol,Solacap,Triflucan,UK-49858,Zonal,Apo Fluconazole,Fluconazol Isis,Fluconazol ratiopharm,UK 49858,UK49858
D058886 Sterol 14-Demethylase An NADPH-dependent P450 enzyme that plays an essential role in the sterol biosynthetic pathway by catalyzing the demethylation of 14-methyl sterols such as lanosterol. The enzyme acts via the repeated hydroxylation of the 14-methyl group, resulting in its stepwise conversion into an alcohol, an aldehyde and then a carboxylate, which is removed as formic acid. Sterol 14-demethylase is an unusual cytochrome P450 enzyme in that it is found in a broad variety of organisms including ANIMALS; PLANTS; FUNGI; and protozoa. Sterol 14-Demethylases,CYP51 Cytochrome P-450,Cytochrome P-450 CYP51,Eburicol 14 alpha-Demethylase,Eburicol 14alpha-Demethylase,Lanosterol 14 alpha-Demethylase,Obtusifoliol 14alpha-Demethylase,Sterol 14-alpha-Demethylase,14 alpha-Demethylase, Eburicol,14 alpha-Demethylase, Lanosterol,14-Demethylase, Sterol,14-Demethylases, Sterol,14-alpha-Demethylase, Sterol,14alpha-Demethylase, Eburicol,14alpha-Demethylase, Obtusifoliol,CYP51 Cytochrome P 450,CYP51, Cytochrome P-450,Cytochrome P 450 CYP51,Cytochrome P-450, CYP51,Eburicol 14 alpha Demethylase,Eburicol 14alpha Demethylase,Lanosterol 14 alpha Demethylase,Obtusifoliol 14alpha Demethylase,P-450 CYP51, Cytochrome,P-450, CYP51 Cytochrome,Sterol 14 Demethylase,Sterol 14 Demethylases,Sterol 14 alpha Demethylase
D065607 Cytochrome P-450 Enzyme Inhibitors Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. Cytochrome P-450 Inhibitors,Cytochrome P-450 Monooxygenase Inhibitors,Cytochrome P-450 Oxygenase Inhibitors,Cytochrome P-450-Dependent Monooxygenase Inhibitors,P-450 Enzyme Inhibitors,P450 Enzyme Inhibitors,Cytochrome P 450 Dependent Monooxygenase Inhibitors,Cytochrome P 450 Enzyme Inhibitors,Cytochrome P 450 Inhibitors,Cytochrome P 450 Monooxygenase Inhibitors,Cytochrome P 450 Oxygenase Inhibitors,Enzyme Inhibitors, P-450,Enzyme Inhibitors, P450,Inhibitors, Cytochrome P-450,Inhibitors, P-450 Enzyme,Inhibitors, P450 Enzyme,P 450 Enzyme Inhibitors,P-450 Inhibitors, Cytochrome

Related Publications

Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
March 2014, European journal of medicinal chemistry,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
June 2005, Acta crystallographica. Section C, Crystal structure communications,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
April 2011, Journal of enzyme inhibition and medicinal chemistry,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
February 1996, Chemical & pharmaceutical bulletin,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
June 2012, Acta crystallographica. Section E, Structure reports online,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
November 2008, Acta crystallographica. Section E, Structure reports online,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
May 2011, ChemMedChem,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
September 2001, Chemical & pharmaceutical bulletin,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
May 2012, Acta crystallographica. Section E, Structure reports online,
Yongwei Jiang, and Yongbin Cao, and Jun Zhang, and Yan Zou, and Xiaoyun Chai, and Honggang Hu, and Qingjie Zhao, and Qiuye Wu, and Dazhi Zhang, and Yuanying Jiang, and Qingyan Sun
December 1997, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!